Literatur
- 1
Glade M J.
Food, nutrition, and the prevention of cancer: a global perspective. American Institute
for Cancer Research/World Cancer Research Fund, American Institute for Cancer Research,
1997.
Nutrition.
1999;
15
523-526
- 2
Fernandez E, La Vecchia C, Decarli A.
Attributable risks for pancreatic cancer in northern Italy.
Cancer Epidemiol Biomarkers Prev.
1996;
5
23-27
- 3
Ji B T, Chow W H, Gridley G. et al .
Dietary factors and the risk of pancreatic cancer: a case-control study in Shanghai
China.
Cancer Epidemiol Biomarkers Prev.
1995;
4
885-893
- 4
Soler M, Chatenoud L, La Vecchia C. et al .
Diet, alcohol, coffee and pancreatic cancer: final results from an Italian study.
Eur J Cancer Prev.
1998;
7
455-460
- 5
Nkondjock A, Krewski D, Johnson K C. et al .
Dietary patterns and risk of pancreatic cancer.
Int J Cancer.
2005;
114
817-823
- 6
Nothlings U, Wilkens L R, Murphy S P. et al .
Meat and fat intake as risk factors for pancreatic cancer: the multiethnic cohort
study.
J Natl Cancer Inst.
2005;
97
1458-1465
- 7
Michaud D S, Giovannucci E, Willett W C. et al .
Dietary meat, dairy products, fat, and cholesterol and pancreatic cancer risk in a
prospective study.
Am J Epidemiol.
2003;
157
1115-1125
- 8
Michaud D S, Skinner H G, Wu K. et al .
Dietary patterns and pancreatic cancer risk in men and women.
J Natl Cancer Inst.
2005;
97
518-524
- 9
Hine R J, Srivastava S, Milner J A. et al .
Nutritional links to plausible mechanisms underlying pancreatic cancer: a conference
report.
Pancreas.
2003;
27
356-366
- 10
Bueno de Mesquita H B, Maisonneuve P, Runia S. et al .
Intake of foods and nutrients and cancer of the exocrine pancreas: a population-based
case-control study in The Netherlands.
Int J Cancer.
1991;
48
540-549
- 11
Lyon J L, Slattery M L, Mahoney A W. et al .
Dietary intake as a risk factor for cancer of the exocrine pancreas.
Cancer Epidemiol Biomarkers Prev.
1993;
2
513-518
- 12
Fraser G E.
Associations between diet and cancer, ischemic heart disease, and all-cause mortality
in non-Hispanic white California Seventh-day Adventists.
Am J Clin Nutr.
1999;
70
532S-538S
- 13
Mills P K, Beeson W L, Abbey D E. et al .
Dietary habits and past medical history as related to fatal pancreas cancer risk among
Adventists.
Cancer.
1988;
61
2578-2585
- 14
Chan J M, Wang F, Holly E A.
Vegetable and fruit intake and pancreatic cancer in a population-based case-control
study in the San Francisco bay area.
Cancer Epidemiol Biomarkers Prev.
2005;
14
2093-2097
- 15
Negri E, La Vecchia C, Franceschi S. et al .
Vegetable and fruit consumption and cancer risk.
Int J Cancer.
1991;
48
350-354
- 16
Larsson S C, Hakansson N, Naslund I. et al .
Fruit and vegetable consumption in relation to pancreatic cancer risk: a prospective
study.
Cancer Epidemiol Biomarkers Prev.
2006;
15
301-305
- 17
Vainio H, Weiderpass E.
Fruit and vegetables in cancer prevention.
Nutr Cancer.
2006;
54
111-142
- 18
Lin Y, Tamakoshi A, Hayakawa T. et al .
Nutritional factors and risk of pancreatic cancer: a population-based case-control
study based on direct interview in Japan.
J Gastroenterol.
2005;
40
297-301
- 19
Stolzenberg-Solomon R Z, Pietinen P, Taylor P R. et al .
Prospective study of diet and pancreatic cancer in male smokers.
Am J Epidemiol.
2002;
155
783-792
- 20
Zhang J, Zhao Z, Berkel H J.
Animal fat consumption and pancreatic cancer incidence: evidence of interaction with
cigarette smoking.
Ann Epidemiol.
2005;
15
500-508
- 21
Anderson K E, Sinha R, Kulldorff M. et al .
Meat intake and cooking techniques: associations with pancreatic cancer.
Mutat Res.
2002;
506 - 507
225-231
- 22
Anderson K E, Kadlubar F F, Kulldorff M. et al .
Dietary intake of heterocyclic amines and benzo(a)pyrene: associations with pancreatic
cancer.
Cancer Epidemiol Biomarkers Prev.
2005;
14
2261-2265
- 23
Ghadirian P, Baillargeon J, Simard A. et al .
Food habits and pancreatic cancer: a case-control study of the Francophone community
in Montreal, Canada.
Cancer Epidemiol Biomarkers Prev.
1995;
4
895-899
- 24
Fernandez E, Chatenoud L, La Vecchia C. et al .
Fish consumption and cancer risk.
Am J Clin Nutr.
1999;
70
85-90
- 25
Michaud D S, Liu S, Giovannucci E. et al .
Dietary sugar, glycemic load, and pancreatic cancer risk in a prospective study.
J Natl Cancer Inst.
2002;
94
1293-1300
- 26
Silvera S A, Rohan T E, Jain M. et al .
Glycemic index, glycemic load, and pancreatic cancer risk (Canada).
Cancer Causes Control.
2005;
16
431-436
- 27
Schernhammer E S, Hu F B, Giovannucci E. et al .
Sugar-sweetened soft drink consumption and risk of pancreatic cancer in two prospective
cohorts.
Cancer Epidemiol Biomarkers Prev.
2005;
14
2098-2105
- 28
Lin Y, Tamakoshi A, Kawamura T. et al .
Risk of pancreatic cancer in relation to alcohol drinking, coffee consumption and
medical history: findings from the Japan collaborative cohort study for evaluation
of cancer risk.
Int J Cancer.
2002;
99
742-746
- 29
Michaud D S, Giovannucci E, Willett W C. et al .
Coffee and alcohol consumption and the risk of pancreatic cancer in two prospective
United States cohorts.
Cancer Epidemiol Biomarkers Prev.
2001;
10
429-437
- 30
Silverman D T.
Risk factors for pancreatic cancer: a case-control study based on direct interviews.
Teratog Carcinog Mutagen.
2001;
21
7-25
- 31
Brown L M.
Epidemiology of alcohol-associated cancers.
Alcohol.
2005;
35
161-168
- 32
Ye W, Lagergren J, Weiderpass E. et al .
Alcohol abuse and the risk of pancreatic cancer.
Gut.
2002;
51
236-239
- 33
Talamini G, Bassi C, Falconi M. et al .
Alcohol and smoking as risk factors in chronic pancreatitis and pancreatic cancer.
Dig Dis Sci.
1999;
44
1303-1311
- 34
MacMahon B, Yen S, Trichopoulos D. et al .
Coffee and cancer of the pancreas.
N Engl J Med.
1981;
304
630-633
- 35
Gullo L, Pezzilli R, Morselli-Labate A M.
Coffee and cancer of the pancreas: an Italian multicenter study. The Italian Pancreatic
Cancer Study Group.
Pancreas.
1995;
11
223-229
- 36
Lyon J L, Mahoney A W, French T K. et al .
Coffee consumption and the risk of cancer of the exocrine pancreas: a case-control
study in a low-risk population.
Epidemiology.
1992;
3
164-170
- 37
Harnack L J, Anderson K E, Zheng W. et al .
Smoking, alcohol, coffee, and tea intake and incidence of cancer of the exocrine pancreas:
the Iowa Women’s Health Study.
Cancer Epidemiol Biomarkers Prev.
1997;
6
1081-1086
- 38
Qiu D, Kurosawa M, Lin Y. et al .
Overview of the epidemiology of pancreatic cancer focusing on the JACC Study.
J Epidemiol.
2005;
15 (Suppl 2)
S157-167
- 39
Tavani A, La Vecchia C.
Coffee and cancer: a review of epidemiological studies, 1990 - 1999.
Eur J Cancer Prev.
2000;
9
241-256
- 40
La Vecchia C, Negri E, Franceschi S. et al .
Tea consumption and cancer risk.
Nutr Cancer.
1992;
17
27-31
- 41
Nagano J, Kono S, Preston D L. et al .
A prospective study of green tea consumption and cancer incidence, Hiroshima and Nagasaki
(Japan).
Cancer Causes Control.
2001;
12
501-508
- 42
Hemminki K, Dong C, Vaittinen P.
Cancer risks to spouses and offspring in the Family-Cancer Database.
Genet Epidemiol.
2001;
20
247-257
- 43
Hemminki K, Jiang Y.
Cancer risks among long-standing spouses.
Br J Cancer.
2002;
86
1737-1740
- 44
Nilsen T I, Vatten L J.
A prospective study of lifestyle factors and the risk of pancreatic cancer in Nord-Trondelag,
Norway.
Cancer Causes Control.
2000;
11
645-652
- 45
Berrington de Gonzalez A, Sweetland S, Spencer E.
A meta-analysis of obesity and the risk of pancreatic cancer.
Br J Cancer.
2003;
89
519-523
- 46
Michaud D S, Giovannucci E, Willett W C. et al .
Physical activity, obesity, height, and the risk of pancreatic cancer.
Jama.
2001;
286
921-929
- 47
Patel A V, Rodriguez C, Bernstein L. et al .
Obesity, recreational physical activity, and risk of pancreatic cancer in a large
U.S. Cohort.
Cancer Epidemiol Biomarkers Prev.
2005;
14
459-466
- 48
Rapp K, Schroeder J, Klenk J. et al .
Obesity and incidence of cancer: a large cohort study of over 145,000 adults in Austria.
Br J Cancer.
2005;
93
1062-1067
- 49
Larsson S C, Permert J, Hakansson N. et al .
Overall obesity, abdominal adiposity, diabetes and cigarette smoking in relation to
the risk of pancreatic cancer in two Swedish population-based cohorts.
Br J Cancer.
2005;
93
1310-1315
- 50
Berrington de Gonzalez A, Spencer E A, Bueno-de-Mesquita H B. et al .
Anthropometry, physical activity, and the risk of pancreatic cancer in the European
prospective investigation into cancer and nutrition.
Cancer Epidemiol Biomarkers Prev.
2006;
15
879-885
- 51
Silverman D T, Swanson C A, Gridley G. et al .
Dietary and nutritional factors and pancreatic cancer: a case-control study based
on direct interviews.
J Natl Cancer Inst.
1998;
90
1710-1719
- 52
Stolzenberg-Solomon R Z, Pietinen P, Taylor P R. et al .
A prospective study of medical conditions, anthropometry, physical activity, and pancreatic
cancer in male smokers (Finland).
Cancer Causes Control.
2002;
13
417-426
- 53
Hanley A J, Johnson K C, Villeneuve P J. et al .
Physical activity, anthropometric factors and risk of pancreatic cancer: results from
the Canadian enhanced cancer surveillance system.
Int J Cancer.
2001;
94
140-147
- 54
Coughlin S S, Calle E E, Patel A V. et al .
Predictors of pancreatic cancer mortality among a large cohort of United States adults.
Cancer Causes Control.
2000;
11
915-923
- 55
Lin Y, Tamakoshi A, Kawamura T. et al .
A prospective cohort study of cigarette smoking and pancreatic cancer in Japan.
Cancer Causes Control.
2002;
13
249-254
- 56
Yun Y H, Jung K W, Bae J M. et al .
Cigarette smoking and cancer incidence risk in adult men: National Health Insurance
Corporation Study.
Cancer Detect Prev.
2005;
29
15-24
- 57
Chiu B C, Lynch C F, Cerhan J R. et al .
Cigarette smoking and risk of bladder, pancreas, kidney, and colorectal cancers in
Iowa.
Ann Epidemiol.
2001;
11
28-37
- 58
Bonelli L, Aste H, Bovo P. et al .
Exocrine pancreatic cancer, cigarette smoking, and diabetes mellitus: a case-control
study in northern Italy.
Pancreas.
2003;
27
143-149
- 59
Duell E J, Holly E A, Bracci P M. et al .
A population-based, case-control study of polymorphisms in carcinogen-metabolizing
genes, smoking, and pancreatic adenocarcinoma risk.
J Natl Cancer Inst.
2002;
94
297-306
- 60
Miyasaka K, Kawanami T, Shimokata H. et al .
Inactive aldehyde dehydrogenase-2 increased the risk of pancreatic cancer among smokers
in a Japanese male population.
Pancreas.
2005;
30
95-98
- 61
Wang L, Miao X, Tan W. et al .
Genetic polymorphisms in methylenetetrahydrofolate reductase and thymidylate synthase
and risk of pancreatic cancer.
Clin Gastroenterol Hepatol.
2005;
3
743-751
- 62
Villeneuve P J, Johnson K C, Mao Y. et al .
Environmental tobacco smoke and the risk of pancreatic cancer: findings from a Canadian
population-based case-control study.
Can J Public Health.
2004;
95
32-37
- 63
Alguacil J, Pollan M, Gustavsson P.
Occupations with increased risk of pancreatic cancer in the Swedish population.
Occup Environ Med.
2003;
60
570-576
- 64
Alguacil J, Porta M, Benavides F G. et al .
Occupation and pancreatic cancer in Spain: a case-control study based on job titles.
PANKRAS II Study Group.
Int J Epidemiol.
2000;
29
1004-1013
- 65
Laakkonen A, Kauppinen T, Pukkala E.
Cancer risk among Finnish food industry workers.
Int J Cancer.
2006;
118
2567-2571
- 66
Fryzek J P, Garabrant D H, Harlow S D. et al .
A case-control study of self-reported exposures to pesticides and pancreas cancer
in southeastern Michigan.
Int J Cancer.
1997;
72
62-67
- 67
Ji B T, Silverman D T, Stewart P A. et al .
Occupational exposure to pesticides and pancreatic cancer.
Am J Ind Med.
2001;
39
92-99
- 68
Ojajarvi I A, Partanen T J, Ahlbom A. et al .
Occupational exposures and pancreatic cancer: a meta-analysis.
Occup Environ Med.
2000;
57
316-324
- 69
Ojajarvi A, Partanen T, Ahlbom A. et al .
Risk of pancreatic cancer in workers exposed to chlorinated hydrocarbon solvents and
related compounds: a meta-analysis.
Am J Epidemiol.
2001;
153
841-850
- 70
Weiderpass E, Vainio H, Kauppinen T. et al .
Occupational exposures and gastrointestinal cancers among Finnish women.
J Occup Environ Med.
2003;
45
305-315
- 71
Yassi A, Tate R B, Routledge M.
Cancer incidence and mortality in workers employed at a transformer manufacturing
plant: update to a cohort study.
Am J Ind Med.
2003;
44
58-62
- 72
Ji J, Hemminki K.
Socioeconomic and occupational risk factors for pancreatic cancer: a cohort study
in Sweden.
J Occup Environ Med.
2006;
48
283-288
- 73
Bjelakovic G, Nikolova D, Simonetti R G. et al .
Antioxidant supplements for prevention of gastrointestinal cancers: a systematic review
and meta-analysis.
Lancet.
2004;
364
1219-1228
- 74
Bjelakovic G, Nikolova D, Simonetti R G. et al .
Antioxidant supplements for preventing gastrointestinal cancers.
Cochrane Database Syst Rev CD004183.
2004;
- 75
Harris R E, Beebe-Donk J, Doss H. et al .
Aspirin, ibuprofen, and other non-steroidal anti-inflammatory drugs in cancer prevention:
a critical review of non-selective COX-2 blockade (review).
Oncol Rep.
2005;
13
559-583
- 76
Jacobs E J, Connell C J, Rodriguez C. et al .
Aspirin use and pancreatic cancer mortality in a large United States cohort.
J Natl Cancer Inst.
2004;
96
524-528
- 77
Coogan P F, Rosenberg L, Palmer J R. et al .
Nonsteroidal anti-inflammatory drugs and risk of digestive cancers at sites other
than the large bowel.
Cancer Epidemiol Biomarkers Prev.
2000;
9
119-123
- 78
Homma T, Tsuchiya R.
The study of the mass screening of persons without symptoms and of the screening of
outpatients with gastrointestinal complaints or icterus for pancreatic cancer in Japan,
using CA 19-9 and elastase-1 or ultrasonography.
Int J Pancreatol.
1991;
9
119-124
- 79
Kim J E, Lee K T, Lee J K. et al .
Clinical usefulness of carbohydrate antigen 19 - 9 as a screening test for pancreatic
cancer in an asymptomatic population.
J Gastroenterol Hepatol.
2004;
19
182-186
- 80
McWilliams R R, Rabe K G, Olswold C. et al .
Risk of malignancy in first-degree relatives of patients with pancreatic carcinoma.
Cancer.
2005;
104
388-394
- 81
Klein A P, Brune K A, Petersen G M. et al .
Prospective risk of pancreatic cancer in familial pancreatic cancer kindreds.
Cancer Res.
2004;
64
2634-2638
- 82
Bartsch D K, Sina-Frey M, Lang S. et al .
CDKN2A germline mutations in familial pancreatic cancer.
Ann Surg.
2002;
236
730-737
- 83
McFaul C D, Greenhalf W, Earl J. et al .
Anticipation in familial pancreatic cancer.
Gut.
2006;
55
252-258
- 84
Tersmette A C, Petersen G M, Offerhaus G J. et al .
Increased risk of incident pancreatic cancer among first-degree relatives of patients
with familial pancreatic cancer.
Clin Cancer Res.
2001;
7
738-744
- 85
Brentnall T A.
Management strategies for patients with hereditary pancreatic cancer.
Curr Treat Options Oncol.
2005;
6
437-445
- 86
Canto M I, Goggins M, Yeo C J. et al .
Screening for pancreatic neoplasia in high-risk individuals: an EUS-based approach.
Clin Gastroenterol Hepatol.
2004;
2
606-621
- 87
Canto M I, Goggins M, Hruban R H. et al .
Screening for early pancreatic neoplasia in high-risk individuals: a prospective controlled
study.
Clin Gastroenterol Hepatol.
2006;
4
766-781; quiz 665
- 88
Giardiello F M, Brensinger J D, Tersmette A C. et al .
Very high risk of cancer in familial Peutz-Jeghers syndrome.
Gastroenterology.
2000;
119
1447-1453
- 89
Lim W, Olschwang S, Keller J J. et al .
Relative frequency and morphology of cancers in STK11 mutation carriers.
Gastroenterology.
2004;
126
1788-1794
- 90
Lynch H T, Brand R E, Hogg D. et al .
Phenotypic variation in eight extended CDKN2A germline mutation familial atypical
multiple mole melanoma-pancreatic carcinoma-prone families: the familial atypical
mole melanoma-pancreatic carcinoma syndrome.
Cancer.
2002;
94
84-96
- 91
Rulyak S J, Brentnall T A, Lynch H T. et al .
Characterization of the neoplastic phenotype in the familial atypical multiple-mole
melanoma-pancreatic carcinoma syndrome.
Cancer.
2003;
98
798-804
- 92
Vasen H F, Gruis N A, Frants R R. et al .
Risk of developing pancreatic cancer in families with familial atypical multiple mole
melanoma associated with a specific 19 deletion of p16 (p16-Leiden).
Int J Cancer.
2000;
87
809-811
- 93
Friedenson B.
BRCA1 and BRCA2 pathways and the risk of cancers other than breast or ovarian.
MedGenMed.
2005;
7
60
- 94
Asperen C J van, Brohet R M, Meijers-Heijboer E J. et al .
Cancer risks in BRCA2 families: estimates for sites other than breast and ovary.
J Med Genet.
2005;
42
711-719
- 95
Thompson D, Easton D F.
Cancer Incidence in BRCA1 mutation carriers.
J Natl Cancer Inst.
2002;
94
1358-1365
- 96
Lilley M, Gilchrist D.
The hereditary spectrum of pancreatic cancer: the Edmonton experience.
Can J Gastroenterol.
2004;
18
17-21
- 97
Aarnio M, Sankila R, Pukkala E. et al .
Cancer risk in mutation carriers of DNA-mismatch-repair genes.
Int J Cancer.
1999;
81
214-218
- 98
Geoffroy-Perez B, Janin N, Ossian K. et al .
Cancer risk in heterozygotes for ataxia-telangiectasia.
Int J Cancer.
2001;
93
288-293
- 99
Giardiello F M, Offerhaus G J, Lee D H. et al .
Increased risk of thyroid and pancreatic carcinoma in familial adenomatous polyposis.
Gut.
1993;
34
1394-1396
- 100
Couch F J, Johnson M R, Rabe K. et al .
Germ line Fanconi anemia complementation group C mutations and pancreatic cancer.
Cancer Res.
2005;
65
383-386
- 101
Howes N, Lerch M M, Greenhalf W. et al .
Clinical and genetic characteristics of hereditary pancreatitis in Europe.
Clin Gastroenterol Hepatol.
2004;
2
252-261
- 102
Lowenfels A B, Maisonneuve P, DiMagno E P. et al .
Hereditary pancreatitis and the risk of pancreatic cancer. International Hereditary
Pancreatitis Study Group.
J Natl Cancer Inst.
1997;
89
442-446
- 103
Kimmey M B, Bronner M P, Byrd D R. et al .
Screening and surveillance for hereditary pancreatic cancer.
Gastrointest Endosc.
2002;
56
S82-86
- 104
Bansal P, Sonnenberg A.
Pancreatitis is a risk factor for pancreatic cancer.
Gastroenterology.
1995;
109
247-251
- 105
Karlson B M, Ekbom A, Josefsson S. et al .
The risk of pancreatic cancer following pancreatitis: an association due to confounding?.
Gastroenterology.
1997;
113
587-592
- 106
Lowenfels A B, Maisonneuve P, Cavallini G. et al .
Pancreatitis and the risk of pancreatic cancer. International Pancreatitis Study Group.
N Engl J Med.
1993;
328
1433-1437
- 107
Malka D, Hammel P, Maire F. et al .
Risk of pancreatic adenocarcinoma in chronic pancreatitis.
Gut.
2002;
51
849-852
- 108
Talamini G, Falconi M, Bassi C. et al .
Incidence of cancer in the course of chronic pancreatitis.
Am J Gastroenterol.
1999;
94
1253-1260
- 109
Chari S T, Leibson C L, Rabe K G. et al .
Probability of pancreatic cancer following diabetes: a population-based study.
Gastroenterology.
2005;
129
504-511
- 110
Coughlin S S, Calle E E, Teras L R. et al .
Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults.
Am J Epidemiol.
2004;
159
1160-1167
- 111
Huxley R, Ansary-Moghaddam A, Berrington de Gonzalez A. et al .
Type-II diabetes and pancreatic cancer. A meta-analysis of 36 studies.
Br J Cancer.
2005;
92
2076-2083
- 112
Stolzenberg-Solomon R Z, Graubard B I, Chari S. et al .
Insulin, glucose, insulin resistance, and pancreatic cancer in male smokers.
Jama.
2005;
294
2872-2878
- 113
Wideroff L, Gridley G, Mellemkjaer L. et al .
Cancer incidence in a population-based cohort of patients hospitalized with diabetes
mellitus in Denmark.
J Natl Cancer Inst.
1997;
89
1360-1365
- 114
Calle E E, Murphy T K, Rodriguez C. et al .
Diabetes mellitus and pancreatic cancer mortality in a prospective cohort of United
States adults.
Cancer Causes Control.
1998;
9
403-410
- 115
Chow W H, Gridley G, Nyren O. et al .
Risk of pancreatic cancer following diabetes mellitus: a nationwide cohort study in
Sweden.
J Natl Cancer Inst.
1995;
87
930-931
- 116
Silverman D T, Schiffman M, Everhart J. et al .
Diabetes mellitus, other medical conditions and familial history of cancer as risk
factors for pancreatic cancer.
Br J Cancer.
1999;
80
1830-1837
- 117
Everhart J, Wright D.
Diabetes mellitus as a risk factor for pancreatic cancer. A meta-analysis.
Jama.
1995;
273
1605-1609
- 118
Gullo L, Pezzilli R, Morselli-Labate A M.
Diabetes and the risk of pancreatic cancer. Italian Pancreatic Cancer Study Group.
N Engl J Med.
1994;
331
81-84
- 119
Rousseau M C, Parent M E, Pollak M N. et al .
Diabetes mellitus and cancer risk in a population-based case-control study among men
from Montreal, Canada.
Int J Cancer.
2006;
118
2105-2109
- 120
Bjornsson E, Ismael S, Nejdet S. et al .
Severe jaundice in Sweden in the new millennium: causes, investigations, treatment
and prognosis.
Scand J Gastroenterol.
2003;
38
86-94
- 121
Reisman Y, Gips C H, Lavelle S M. et al .
Clinical presentation of (subclinical) jaundice - the Euricterus project in The Netherlands.
United Dutch Hospitals and Euricterus Project Management Group.
Hepatogastroenterology.
1996;
43
1190-1195
- 122
Watanabe I, Sasaki S, Konishi M. et al .
Onset symptoms and tumor locations as prognostic factors of pancreatic cancer.
Pancreas.
2004;
28
160-165
- 123
Balthazar E J.
Pancreatitis associated with pancreatic carcinoma. Preoperative diagnosis: role of
CT imaging in detection and evaluation.
Pancreatology.
2005;
5
330-344
- 124
Mujica V R, Barkin J S, Go V L.
Acute pancreatitis secondary to pancreatic carcinoma. Study Group Participants.
Pancreas.
2000;
21
329-332
- 125
Adamek H E, Albert J, Breer H. et al .
Pancreatic cancer detection with magnetic resonance cholangiopancreatography and endoscopic
retrograde cholangiopancreatography: a prospective controlled study.
Lancet.
2000;
356
190-193
- 126
Hanninen E L, Ricke J, Amthauer H. et al .
Magnetic resonance cholangiopancreatography: image quality, ductal morphology, and
value of additional T2- and T1-weighted sequences for the assessment of suspected
pancreatic cancer.
Acta Radiol.
2005;
46
117-125
- 127
Forsmark C E, Lambiase L, Vogel S B.
Diagnosis of pancreatic cancer and prediction of unresectability using the tumor-associated
antigen CA 19-9.
Pancreas.
1994;
9
731-734
- 128
Nazli O, Bozdag A D, Tansug T. et al .
The diagnostic importance of CEA and CA 19 - 9 for the early diagnosis of pancreatic
carcinoma.
Hepatogastroenterology.
2000;
47
1750-1752
- 129
Ritts R E Jr, Nagorney D M, Jacobsen D J. et al .
Comparison of preoperative serum CA 19-9 levels with results of diagnostic imaging
modalities in patients undergoing laparotomy for suspected pancreatic or gallbladder
disease.
Pancreas.
1994;
9
707-716
- 130
Tessler D A, Catanzaro A, Velanovich V. et al .
Predictors of cancer in patients with suspected pancreatic malignancy without a tissue
diagnosis.
Am J Surg.
2006;
191
191-197
- 131
Agarwal B, Abu-Hamda E, Molke K L. et al .
Endoscopic ultrasound-guided fine needle aspiration and multidetector spiral CT in
the diagnosis of pancreatic cancer.
Am J Gastroenterol.
2004;
99
844-850
- 132
Klapman J B, Chang K J, Lee J G. et al .
Negative predictive value of endoscopic ultrasound in a large series of patients with
a clinical suspicion of pancreatic cancer.
Am J Gastroenterol.
2005;
100
2658-2661
- 133
Varadarajulu S, Wallace M B.
Applications of endoscopic ultrasonography in pancreatic cancer.
Cancer Control.
2004;
11
15-22
- 134
David O, Green L, Reddy V. et al .
Pancreatic masses: a multi-institutional study of 364 fine-needle aspiration biopsies
with histopathologic correlation.
Diagn Cytopathol.
1998;
19
423-427
- 135
Bipat S, Phoa S S, Delden O M. et al .
Ultrasonography, computed tomography and magnetic resonance imaging for diagnosis
and determining resectability of pancreatic adenocarcinoma: a meta-analysis.
J Comput Assist Tomogr.
2005;
29
438-445
- 136
Dewitt van J, Devereaux B M, Lehman G A. et al .
Comparison of endoscopic ultrasound and computed tomography for the preoperative evaluation
of pancreatic cancer: a systematic review.
Clin Gastroenterol Hepatol.
2006;
4
717-725; quiz 664
- 137
Romagnuolo J, Bardou M, Rahme E. et al .
Magnetic resonance cholangiopancreatography: a meta-analysis of test performance in
suspected biliary disease.
Ann Intern Med.
2003;
139
547-557
- 138
Pakzad F, Groves A M, Ell P J.
The role of positron emission tomography in the management of pancreatic cancer.
Semin Nucl Med.
2006;
36
248-256
- 139
Schachter P P, Avni Y, Shimonov M. et al .
The impact of laparoscopy and laparoscopic ultrasonography on the management of pancreatic
cancer.
Arch Surg.
2000;
135
1303-1307
- 140
Vollmer C M, Drebin J A, Middleton W D. et al .
Utility of staging laparoscopy in subsets of peripancreatic and biliary malignancies.
Ann Surg.
2002;
235
1-7
- 141
van der Waaij L A, Dullemen H M, Porte R J.
Cyst fluid analysis in the differential diagnosis of pancreatic cystic lesions. A
pooled analysis.
Gastrointest Endosc.
2005;
62
383-389
- 142
Fong van Y, Blumgart L H, Fortner J G. et al .
Pancreatic or liver resection for malignancy is safe and effective for the elderly.
Ann Surg.
1995;
222
426-434; discussion 434 - 437
- 143
Lightner A M, Glasgow R E, Jordan T H. et al .
Pancreatic resection in the elderly.
J Am Coll Surg.
2004;
198
697-706
- 144
Lillemoe K D, Cameron J L, Hardacre J M. et al .
Is prophylactic gastrojejunostomy indicated for unresectable periampullary cancer?
A prospective randomized trial.
Ann Surg.
1999;
230
322-328; discussion 328 - 330
- 145
American College of Physicians .
Guidelines for assessing and managing the perioperative risk from coronary artery
disease associated with major noncardiac surgery.
Ann Intern Med.
1997;
127
309-312
- 146
Wagner M, Redaelli C, Lietz M. et al .
Curative resection is the single most important factor determining outcome in patients
with pancreatic adenocarcinoma.
Br J Surg.
2004;
91
586-594
- 147
Fuhrman G M, Leach S D, Staley C A. et al .
Rationale for en bloc vein resection in the treatment of pancreatic adenocarcinoma
adherent to the superior mesenteric-portal vein confluence. Pancreatic Tumor Study
Group.
Ann Surg.
1996;
223
154-162
- 148
Leach S D, Lee J E, Charnsangavej C. et al .
Survival following pancreaticoduodenectomy with resection of the superior mesenteric-portal
vein confluence for adenocarcinoma of the pancreatic head.
Br J Surg.
1998;
85
611-617
- 149
Sasson A R, Hoffman J P, Ross E A. et al .
En bloc resection for locally advanced cancer of the pancreas: is it worthwhile?.
J Gastrointest Surg.
2002;
6
147-157; discussion 157 - 158
- 150
Nakao A, Takeda S, Inoue S. et al .
Indications and techniques of extended resection for pancreatic cancer.
World J Surg.
2006;
30
976-982; discussion 983 - 984
- 151
Varadhachary G R, Tamm E P, Abbruzzese J L. et al .
Borderline resectable pancreatic cancer: definitions, management, and role of preoperative
therapy.
Ann Surg Oncol.
2006;
13
1035-1046
- 152
Siriwardana H P, Siriwardena A K.
Systematic review of outcome of synchronous portal-superior mesenteric vein resection
during pancreatectomy for cancer.
Br J Surg.
2006;
93
662-673
- 153
Carrere N, Sauvanet A, Goere D. et al .
Pancreaticoduodenectomy with mesentericoportal vein resection for adenocarcinoma of
the pancreatic head.
World J Surg.
2006;
30
1526-1535
- 154
Riediger H, Makowiec F, Fischer E. et al .
Postoperative morbidity and long-term survival after pancreaticoduodenectomy with
superior mesenterico-portal vein resection.
J Gastrointest Surg.
2006;
10
1106-1115
- 155
Bachellier P, Nakano H, Oussoultzoglou P D. et al .
Is pancreaticoduodenectomy with mesentericoportal venous resection safe and worthwhile?.
Am J Surg.
2001;
182
120-129
- 156
Li B, Chen F Z, Ge X H. et al .
Pancreatoduodenectomy with vascular reconstruction in treating carcinoma of the pancreatic
head.
Hepatobiliary Pancreat Dis Int.
2004;
3
612-615
- 157
Settmacher U, Langrehr J M, Husmann I. et al .
Reconstruction of visceral arteries with homografts in excision of the pancreas.
Chirurg.
2004;
75
1199-1206
- 158
Schwarz R E.
Technical considerations to maintain a low frequency of postoperative biliary stent-associated
infections.
J Hepatobiliary Pancreat Surg.
2002;
9
93-97
- 159
Gerke H, White R, Byrne M F. et al .
Complications of pancreaticoduodenectomy after neoadjuvant chemoradiation in patients
with and without preoperative biliary drainage.
Dig Liver Dis.
2004;
36
412-418
- 160
Jagannath P, Dhir V, Shrikhande S. et al .
Effect of preoperative biliary stenting on immediate outcome after pancreaticoduodenectomy.
Br J Surg.
2005;
92
356-361
- 161
Martignoni M E, Wagner M, Krahenbuhl L. et al .
Effect of preoperative biliary drainage on surgical outcome after pancreatoduodenectomy.
Am J Surg.
2001;
181
52-59; discussion 87
- 162
Sohn T A, Yeo C J, Cameron J L. et al .
Do preoperative biliary stents increase postpancreaticoduodenectomy complications?.
J Gastrointest Surg.
2000;
4
258-267; discussion 267 - 268
- 163
Targarona E M, Garau J, Munoz-Ramos C. et al .
Single-dose antibiotic prophylaxis in patients at high risk for infection in biliary
surgery: a prospective and randomized study comparing cefonicid with mezlocillin.
Surgery.
1990;
107
327-334
- 164
Kujath P, Bouchard R, Scheele J. et al .
Current perioperative antibiotic prophylaxis.
Chirurg.
2006;
77
490, 492-498
- 165
Connor S, Alexakis N, Garden O J. et al .
Meta-analysis of the value of somatostatin and its analogues in reducing complications
associated with pancreatic surgery.
Br J Surg.
2005;
92
1059-1067
- 166
Bassi C, Dervenis C, Butturini G. et al .
Postoperative pancreatic fistula: an international study group (ISGPF) definition.
Surgery.
2005;
138
8-13
- 167
Finlayson C, Hoffman J, Yeung R. et al .
Intraoperative ultrasound does not improve detection of liver metastases in resectable
pancreatic cancer.
Am J Surg.
1998;
175
99-101
- 168
Kolecki R, Schirmer B.
Intraoperative and laparoscopic ultrasound.
Surg Clin North Am.
1998;
78
251-271
- 169
Warshaw A L, Fernandez-del Castillo C.
Pancreatic carcinoma.
N Engl J Med.
1992;
326
455-465
- 170
Konishi M, Kinoshita T, Nakagohri T. et al .
Prognostic value of cytologic examination of peritoneal washings in pancreatic cancer.
Arch Surg.
2002;
137
475-480
- 171
Yachida S, Fukushima N, Sakamoto M. et al .
Implications of peritoneal washing cytology in patients with potentially resectable
pancreatic cancer.
Br J Surg.
2002;
89
573-578
- 172
Diener M K, Knaebel H P, Heukaufer C. et al .
A Systematic Review and Meta-analysis of Pylorus-preserving Versus Classical Pancreaticoduodenectomy
for Surgical Treatment of Periampullary and Pancreatic Carcinoma.
Ann Surg.
2007;
245
187-200
- 173
Christein J D, Kendrick M L, Iqbal C W. et al .
Distal pancreatectomy for resectable adenocarcinoma of the body and tail of the pancreas.
J Gastrointest Surg.
2005;
9
922-927
- 174
Shimada K, Sakamoto Y, Sano T. et al .
Prognostic factors after distal pancreatectomy with extended lymphadenectomy for invasive
pancreatic adenocarcinoma of the body and tail.
Surgery.
2006;
139
288-295
- 175
Shoup M, Conlon K C, Klimstra D. et al .
Is extended resection for adenocarcinoma of the body or tail of the pancreas justified?.
J Gastrointest Surg.
2003;
7
946-952; discussion 952
- 176
Pedrazzoli S, DiCarlo V, Dionigi R. et al .
Standard versus extended lymphadenectomy associated with pancreatoduodenectomy in
the surgical treatment of adenocarcinoma of the head of the pancreas: a multicenter,
prospective, randomized study. Lymphadenectomy Study Group.
Ann Surg.
1998;
228
508-517
- 177
Farnell M B, Pearson R K, Sarr M G. et al .
A prospective randomized trial comparing standard pancreatoduodenectomy with pancreatoduodenectomy
with extended lymphadenectomy in resectable pancreatic head adenocarcinoma.
Surgery.
2005;
138
618-628; discussion 628 - 630
- 178
Yeo C J, Cameron J L, Lillemoe K D. et al .
Pancreaticoduodenectomy with or without distal gastrectomy and extended retroperitoneal
lymphadenectomy for periampullary adenocarcinoma, part 2: randomized controlled trial
evaluating survival, morbidity, and mortality.
Ann Surg.
2002;
236
355-366; discussion 366 - 368
- 179
Brugge W R, Lauwers G Y, Sahani D. et al .
Cystic neoplasms of the pancreas.
N Engl J Med.
2004;
351
1218-1226
- 180
Brugge W R, Lewandrowski K, Lee-Lewandrowski E. et al .
Diagnosis of pancreatic cystic neoplasms: a report of the cooperative pancreatic cyst
study.
Gastroenterology.
2004;
126
1330-1336
- 181
Sedlack R, Affi A, Vazquez-Sequeiros E. et al .
Utility of EUS in the evaluation of cystic pancreatic lesions.
Gastrointest Endosc.
2002;
56
543-547
- 182
Salvia R, Fernandez-del C astillo C, Bassi C. et al .
Main-duct intraductal papillary mucinous neoplasms of the pancreas: clinical predictors
of malignancy and long-term survival following resection.
Ann Surg.
2004;
239
678-685; discussion 685 - 687
- 183
Bassi C, Salvia R, Molinari E. et al .
Management of 100 consecutive cases of pancreatic serous cystadenoma: wait for symptoms
and see at imaging or vice versa?.
World J Surg.
2003;
27
319-323
- 184
Hirano S, Kondo S, Ambo Y. et al .
Outcome of duodenum-preserving resection of the head of the pancreas for intraductal
papillary-mucinous neoplasm.
Dig Surg.
2004;
21
242-245
- 185
Takada T, Yasuda H, Amano H. et al .
Simultaneous hepatic resection with pancreato-duodenectomy for metastatic pancreatic
head carcinoma: does it improve survival?.
Hepatogastroenterology.
1997;
44
567-573
- 186
Mann O, Strate T, Schneider C. et al .
Surgery for advanced and metastatic pancreatic cancer - current state and perspectives.
Anticancer Res.
2006;
26
681-686
- 187
Shrikhande S V, Kleeff J, Reiser C. et al .
Pancreatic resection for M1 pancreatic ductal adenocarcinoma.
Ann Surg Oncol.
2007;
14
118-127
- 188
Friess H, Kleeff J, Silva J C. et al .
The role of diagnostic laparoscopy in pancreatic and periampullary malignancies.
J Am Coll Surg.
1998;
186
675-682
- 189
Urbach D R, Swanstrom L L, Hansen P D.
The effect of laparoscopy on survival in pancreatic cancer.
Arch Surg.
2002;
137
191-199
- 190
Santoro E, Carlini M, Carboni F.
Laparoscopic pancreatic surgery: indications, techniques and preliminary results.
Hepatogastroenterology.
1999;
46
1174-1180
- 191
Cioc A M, Ellison E C, Proca D M. et al .
Frozen section diagnosis of pancreatic lesions.
Arch Pathol Lab Med.
2002;
126
1169-1173
- 192
Luttges J, Zamboni G, Kloppel G.
Recommendation for the examination of pancreaticoduodenectomy specimens removed from
patients with carcinoma of the exocrine pancreas. A proposal for a standardized pathological
staging of pancreaticoduodenectomy specimens including a checklist.
Dig Surg.
1999;
16
291-296
- 193
Compton C C, Henson D E.
Protocol for the examination of specimens removed from patients with carcinoma of
the exocrine pancreas: a basis for checklists. Cancer Committee, College of American
Pathologists.
Arch Pathol Lab Med.
1997;
121
1129-1136
- 194
Sakata E, Shirai Y, Yokoyama N. et al .
Clinical significance of lymph node micrometastasis in ampullary carcinoma.
World J Surg.
2006;
30
985-991
- 195
Oettle H, Post S, Neuhaus P. et al .
Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent
resection of pancreatic cancer: a randomized controlled trial.
Jama.
2007;
297
267-277
- 196
Stocken D D, Buchler M W, Dervenis C. et al .
Meta-analysis of randomised adjuvant therapy trials for pancreatic cancer.
Br J Cancer.
2005;
92
1372-1381
- 197
Neoptolemos J P, Stocken D D, Friess H. et al .
A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic
cancer.
N Engl J Med.
2004;
350
1200-1210
- 198
Penberthy D R, Rich T A, Shelton C H. et al .
A pilot study of chronomodulated infusional 5-fluorouracil chemoradiation for pancreatic
cancer.
Ann Oncol.
2001;
12
681-684
- 199
Mallinson C N, Rake M O, Cocking J B. et al .
Chemotherapy in pancreatic cancer: results of a controlled, prospective, randomised,
multicentre trial.
Br Med J.
1980;
281
1589-1591
- 200
Palmer K R, Kerr M, Knowles G. et al .
Chemotherapy prolongs survival in inoperable pancreatic carcinoma.
Br J Surg.
1994;
81
882-885
- 201
Glimelius B, Hoffman K, Sjoden P O. et al .
Chemotherapy improves survival and quality of life in advanced pancreatic and biliary
cancer.
Ann Oncol.
1996;
7
593-600
- 202
Yip D, Karapetis C, Strickland A. et al .
Chemotherapy and radiotherapy for inoperable advanced pancreatic cancer.
Cochrane Database Syst Rev 3 CD002093.
2006;
- 203
Burris H A 3rd
, Moore M J, Andersen J. et al .
Improvements in survival and clinical benefit with gemcitabine as first-line therapy
for patients with advanced pancreas cancer: a randomized trial.
J Clin Oncol.
1997;
15
2403-2413
- 204
Storniolo A M, Enas N H, Brown C A. et al .
An investigational new drug treatment program for patients with gemcitabine: results
for over 3000 patients with pancreatic carcinoma.
Cancer.
1999;
85
1261-1268
- 205
Louvet C, Labianca R, Hammel P. et al .
Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally
advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III
trial.
J Clin Oncol.
2005;
23
3509-3516
- 206
Heinemann V, Quietzsch D, Gieseler F. et al .
Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine
alone in advanced pancreatic cancer.
J Clin Oncol.
2006;
24
3946-3952
- 207
Herrmann R, Bodoky G, Rushstaller T. et al .
Gemcitabine (G) plus capecitabine (C) versus G alone in locally advanced or metastatic
pancreatic cancer: a randomized phase III study of the Swiss Group for Clinical Cancer
Research (SAKK) and the Central European Cooperative Oncology Group (CECOG).
J Clin Oncol.
2005;
23
A4010
- 208
Berlin J D, Catalano P, Thomas J P. et al .
Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine
alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology
Group Trial E2297.
J Clin Oncol.
2002;
20
3270-3275
- 209
Van Cutsem E, Velde van de H, Karasek P. et al .
Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo
in advanced pancreatic cancer.
J Clin Oncol.
2004;
22
1430-1438
- 210
Tempero M, Plunkett W, Ruiz Van Haperen V. et al .
Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion
and fixed dose rate infusion in patients with pancreatic adenocarcinoma.
J Clin Oncol.
2003;
21
3402-3408
- 211
Poplin E, Levy D, Berlin J. et al .
Phase III trial of gemcitabine (30 min infusion) versus gemcitabine (fixed-dose rate
infusion (FDR) versus gemcitabine + oxaliplatin (GEMOX) in patients with advanced
pancreatic cancer (E6201).
J Clin Oncol.
2006;
24
LBA4004
- 212
Maisey N, Chau I, Cunningham D. et al .
Multicenter randomized phase III trial comparing protracted venous infusion (PVI)
fluorouracil (5-FU) with PVI 5-FU plus mitomycin in inoperable pancreatic cancer.
J Clin Oncol.
2002;
20
3130-3136
- 213
Ducreux M, Rougier P, Pignon J P. et al .
A randomised trial comparing 5-FU with 5-FU plus cisplatin in advanced pancreatic
carcinoma.
Ann Oncol.
2002;
13
1185-1191
- 214
Lutz M P, Koniger M, Muche R. et al .
A phase II study of weekly 24-h infusion of high-dose 5-fluorouracil in advanced pancreatic
cancer.
Z Gastroenterol.
1999;
37
993-997
- 215
Colucci G, Giuliani F, Gebbia V. et al .
Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced
and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study
of the Gruppo Oncologia dell’Italia Meridionale.
Cancer.
2002;
94
902-910
- 216
Ducreux M, Mitry E, Ould-Kaci M. et al .
Randomized phase II study evaluating oxaliplatin alone, oxaliplatin combined with
infusional 5-FU, and infusional 5-FU alone in advanced pancreatic carcinoma patients.
Ann Oncol.
2004;
15
467-473
- 217
Cunningham D, Chau I, Stocken D D. et al .
Phase III randomized comparison of gemcitabine (GEM) vs. gemcitabine plus capecitabine
(Gem-CAP) in patients with advanced pancreatic cancer.
Eur J Cancer.
2005;
3
PS11
- 218
Di Costanzo F, Carlini P, Doni L. et al .
Gemcitabine with or without continuous infusion 5-FU in advanced pancreatic cancer:
a randomised phase II trial of the Italian oncology group for clinical research (GOIRC).
Br J Cancer.
2005;
93
185-189
- 219
Riess M, Helm A, Niedergethmann I. et al .
A randomised prospective, multicentre phase III trial of gemcitabine, 5-fluorouracil
(5-FU), folinic acid vs. gemcitabine alone in patients with advanced pancreatic cancer.
J Clin Oncol.
2005;
23
A1092
- 220
Moore M J, Goldstein D, Hamm J. et al .
Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced
pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical
Trials Group.
J Clin Oncol.
2007;
15
1960-6
- 221
Kindler H L, Friberg G, Singh D A. et al .
Phase II Trial of Bevacizumab Plus Gemcitabine in Patients With Advanced Pancreatic
Cancer.
J Clin Oncol.
2005;
23
8033-8040
- 222
Kindler H, Niedzwiecki, Hollis D. et al .
A double-blind, placebo controlled, randomized phase III trial of gemcitabine (G)
plus bevacizumab (B) versus gemcitabine plus placebo (P) in patients with advanced
pancreatic cancer (PC): a preliminary analysis of Cancer and Leukemia Group B (CALGB)
80 303.
Proceedings of the ASCO Gastrointestinal Cancers Symposium.
2007;
A108
- 223
Reni M, Passoni P, Bonetto E. et al .
Final results of a prospective trial of a PEFG (Cisplatin, Epirubicin, 5-Fluorouracil,
Gemcitabine) regimen followed by radiotherapy after curative surgery for pancreatic
adenocarcinoma.
Oncology.
2005;
68
239-245
- 224
Lutz M P, Van Cutsem E, Wagener T. et al .
Docetaxel plus gemcitabine or docetaxel plus cisplatin in advanced pancreatic carcinoma:
randomized phase II study 40 984 of the European Organisation for Research and Treatment
of Cancer Gastrointestinal Group.
J Clin Oncol.
2005;
23
9250-9256
- 225
Shepard R C, Levy D E, Berlin J D. et al .
Phase II study of gemcitabine in combination with docetaxel in patients with advanced
pancreatic carcinoma (E1298). A trial of the eastern cooperative oncology group.
Oncology.
2004;
66
303-309
- 226
Ridwelski K, Fahlke J, Kuhn R. et al .
Multicenter phase-I/II study using a combination of gemcitabine and docetaxel in metastasized
and unresectable, locally advanced pancreatic carcinoma.
Eur J Surg Oncol.
2006;
32
297-302
- 227
Jacobs A D, Otero H, Picozzi V J Jr. et al .
Gemcitabine combined with docetaxel for the treatment of unresectable pancreatic carcinoma.
Cancer Invest.
2004;
22
505-514
- 228
Ulrich-Pur H, Raderer M, Verena Kornek G. et al .
Irinotecan plus raltitrexed vs raltitrexed alone in patients with gemcitabine-pretreated
advanced pancreatic adenocarcinoma.
Br J Cancer.
2003;
88
1180-1184
- 229
Tsavaris N, Kosmas C, Skopelitis H. et al .
Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated
advanced pancreatic cancer: A phase II study.
Invest New Drugs.
2005;
23
369-375
- 230
Reni M, Pasetto L, Aprile G. et al .
Raltitrexed-eloxatin salvage chemotherapy in gemcitabine-resistant metastatic pancreatic
cancer.
Br J Cancer.
2006;
94
785-791
- 231
Demols A, Peeters M, Polus M. et al .
Gemcitabine and oxaliplatin (GEMOX) in gemcitabine refractory advanced pancreatic
adenocarcinoma: a phase II study.
Br J Cancer.
2006;
94
481-485
- 232
Oettle H, Arnold D, Esser M. et al .
Paclitaxel as weekly second-line therapy in patients with advanced pancreatic carcinoma.
Anticancer Drugs.
2000;
11
635-638
- 233
Burris H A 3rd
, Rivkin S, Reynolds R. et al .
Phase II trial of oral rubitecan in previously treated pancreatic cancer patients.
Oncologist.
2005;
10
183-190
- 234
Mitry E, Ducreux M, Ould-Kaci M. et al .
Oxaliplatin combined with 5-FU in second line treatment of advanced pancreatic adenocarcinoma.
Results of a phase II trial.
Gastroenterol Clin Biol.
2006;
30
357-363
- 235
Willett C G, Czito B G, Bendell J C. et al .
Locally advanced pancreatic cancer.
J Clin Oncol.
2005;
23
4538-4544
- 236
Moertel C G, Childs D S Jr, Reitemeier R J. et al .
Combined 5-fluorouracil and supervoltage radiation therapy of locally unresectable
gastrointestinal cancer.
Lancet.
1969;
2
865-867
- 237
Moertel C G, Frytak S, Hahn R G. et al .
Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high
dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil),
and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study Group.
Cancer.
1981;
48
1705-1710
- 238
Klaassen D J, MacIntyre J M, Catton G E. et al .
Treatment of locally unresectable cancer of the stomach and pancreas: a randomized
comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance
5-fluorouracil - an Eastern Cooperative Oncology Group study.
J Clin Oncol.
1985;
3
373-378
- 239
Cohen L, Woodruff K H, Hendrickson F R. et al .
Response of pancreatic cancer to local irradiation with high-energy neutrons.
Cancer.
1985;
56
1235-1241
- 240
Cohen S J, Dobelbower R Jr, Lipsitz S. et al .
A randomized phase III study of radiotherapy alone or with 5-fluorouracil and mitomycin-C
in patients with locally advanced adenocarcinoma of the pancreas: Eastern Cooperative
Oncology Group study E8282.
Int J Radiat Oncol Biol Phys.
2005;
62
1345-1350
- 241
Gastrointestinal Tumor Study Group .
Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-modality
therapy (chemotherapy plus radiotherapy) to chemotherapy alone.
J Natl Cancer Inst.
1988;
80
751-755
- 242
Shinchi H, Takao S, Noma H. et al .
Length and quality of survival after external-beam radiotherapy with concurrent continuous
5-fluorouracil infusion for locally unresectable pancreatic cancer.
Int J Radiat Oncol Biol Phys.
2002;
53
146-150
- 243
McGinn C J, Zalupski M M, Shureiqi I. et al .
Phase I trial of radiation dose escalation with concurrent weekly full-dose gemcitabine
in patients with advanced pancreatic cancer.
J Clin Oncol.
2001;
19
4202-4208
- 244
Kachnic L A, Shaw J E, Manning M A. et al .
Gemcitabine following radiotherapy with concurrent 5-fluorouracil for nonmetastatic
adenocarcinoma of the pancreas.
Int J Cancer.
2001;
96
132-139
- 245
Crane C H, Abbruzzese J L, Evans D B. et al .
Is the therapeutic index better with gemcitabine-based chemoradiation than with 5-fluorouracil-based
chemoradiation in locally advanced pancreatic cancer?.
Int J Radiat Oncol Biol Phys.
2002;
52
1293-1302
- 246
Rocha Lima C M, Green M R, Rotche R. et al .
Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine
monotherapy in patients with locally advanced or metastatic pancreatic cancer despite
increased tumor response rate.
J Clin Oncol.
2004;
22
3776-3783
- 247
Chauffert B, Mornex F, Bonnetain F. et al .
Phase III trial comparing initial chemoradiotherapy (intermittent cisplatin and infusional
5-FU) followed by gemcitabine vs. gemcitabine alone in patients with locally advanced
non metastatic pancreatic cancer: A FFCD-SFRO study.
J Clin Oncol.
2006;
24
A4008
- 248
Huguet F, Andre T, Hammel P. et al .
Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced
pancreatic adenocarcinoma in GERCOR Phase II and III studies.
J Clin Oncol.
2007;
20
326-331
- 249
Sa Cunha A, Rault A, Laurent C. et al .
Surgical resection after radiochemotherapy in patients with unresectable adenocarcinoma
of the pancreas.
J Am Coll Surg.
2005;
201
359-365
- 250
Fisher B J, Perera F E, Kocha W. et al .
Analysis of the clinical benefit of 5-fluorouracil and radiation treatment in locally
advanced pancreatic cancer.
Int J Radiat Oncol Biol Phys.
1999;
45
291-295
- 251
Furuse J, Kinoshita T, Kawashima M. et al .
Intraoperative and conformal external-beam radiation therapy with protracted 5-fluorouracil
infusion in patients with locally advanced pancreatic carcinoma.
Cancer.
2003;
97
1346-1352
- 252
Brunner T B, Grabenbauer G G, Kastl S. et al .
Preoperative Chemoradiation in Locally Advanced Pancreatic Carcinoma: A Phase II Study.
Onkologie.
2000;
23
436-442
- 253
Ikeda M, Okada S, Tokuuye K. et al .
A phase I trial of weekly gemcitabine and concurrent radiotherapy in patients with
locally advanced pancreatic cancer.
Br J Cancer.
2002;
86
1551-1554
- 254
Talamonti M S, Catalano P J, Vaughn D J. et al .
Eastern Cooperative Oncology Group Phase I trial of protracted venous infusion fluorouracil
plus weekly gemcitabine with concurrent radiation therapy in patients with locally
advanced pancreas cancer: a regimen with unexpected early toxicity.
J Clin Oncol.
2000;
18
3384-3389
- 255
Brunner T B, Grabenbauer G G, Klein P. et al .
Phase I trial of strictly time-scheduled gemcitabine and cisplatin with concurrent
radiotherapy in patients with locally advanced pancreatic cancer.
Int J Radiat Oncol Biol Phys.
2003;
55
144-153
- 256
Micke O, Hesselmann S, Bruns F. et al .
Results and follow-up of locally advanced cancer of the exocrine pancreas treated
with radiochemotherapy.
Anticancer Res.
2005;
25
1523-1530
- 257
Xiong H Q, Rosenberg A, LoBuglio A. et al .
Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in
combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II
Trial.
J Clin Oncol.
2004;
22
2610-2616
- 258
Bramhall S R, Rosemurgy A, Brown P D. et al .
Marimastat as first-line therapy for patients with unresectable pancreatic cancer:
a randomized trial.
J Clin Oncol.
2001;
19
3447-3455
- 259
Moore M J, Hamm J, Dancey J. et al .
Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12 - 9566
in patients with advanced or metastatic adenocarcinoma of the pancreas: a phase III
trial of the National Cancer Institute of Canada Clinical Trials Group.
J Clin Oncol.
2003;
21
3296-3302
- 260
Beger H G, Link K H, Gansauge F.
Adjuvant regional chemotherapy in advanced pancreatic cancer: results of a prospective
study.
Hepatogastroenterology.
1998;
45
638-643
- 261
Ghaneh P, Neoptolemos J P.
Conclusions from the European Study Group for Pancreatic Cancer adjuvant trial of
chemoradiotherapy and chemotherapy for pancreatic cancer.
Surg Oncol Clin N Am.
2004;
13
567-587, vii-viii
- 262
Lohr M, Hoffmeyer A, Kroger J. et al .
Microencapsulated cell-mediated treatment of inoperable pancreatic carcinoma.
Lancet.
2001;
357
1591-1592
- 263
Mercadante S.
Pain treatment and outcomes for patients with advanced cancer who receive follow-up
care at home.
Cancer.
1999;
85
1849-1858
- 264
Zech D F, Grond S, Lynch J. et al .
Validation of World Health Organization Guidelines for cancer pain relief: a 10-year
prospective study.
Pain.
1995;
63
65-76
- 265
Marinangeli F, Ciccozzi A, Leonardis M. et al .
Use of strong opioids in advanced cancer pain: a randomized trial.
J Pain Symptom Manage.
2004;
27
409-416
- 266
Grahm A L, Andren-Sandberg A.
Prospective evaluation of pain in exocrine pancreatic cancer.
Digestion.
1997;
58
542-549
- 267
Caraceni A, Portenoy R K.
Pain management in patients with pancreatic carcinoma.
Cancer.
1996;
78
639-653
- 268
Ross G J, Kessler H B, Clair M R. et al .
Sonographically guided paracentesis for palliation of symptomatic malignant ascites.
Am J Roentgenol.
1989;
153
1309-1311
- 269
McNicol E, Strassels S, Goudas L. et al .
Nonsteroidal anti-inflammatory drugs, alone or combined with opioids, for cancer pain:
a systematic review.
J Clin Oncol.
2004;
22
1975-1992
- 270
Carr D B, Goudas L C, Balk E M. et al .
Evidence report on the treatment of pain in cancer patients.
J Natl Cancer Inst Monogr.
2004;
32
23-31
- 271
Payne R, Mathias S D, Pasta D J. et al .
Quality of life and cancer pain: satisfaction and side effects with transdermal fentanyl
versus oral morphine.
J Clin Oncol.
1998;
16
1588-1593
- 272
De Conno F, Ripamonti C, Saita L. et al .
Role of rectal route in treating cancer pain: a randomized crossover clinical trial
of oral versus rectal morphine administration in opioid-naive cancer patients with
pain.
J Clin Oncol.
1995;
13
1004-1008
- 273
Cherny N I.
The management of cancer pain.
CA Cancer J Clin.
2000;
50
70-116; quiz 117 - 120
- 274
Gilmer-Hill H S, Boggan J E, Smith K A. et al .
Intrathecal morphine delivered via subcutaneous pump for intractable pain in pancreatic
cancer.
Surg Neurol.
1999;
51
6-11
- 275
Staats P S, Hekmat H, Sauter P. et al .
The effects of alcohol celiac plexus block, pain, and mood on longevity in patients
with unresectable pancreatic cancer: a double-blind, randomized, placebo-controlled
study.
Pain Med.
2001;
2
28-34
- 276
Eisenberg E, Carr D B, Chalmers T C.
Neurolytic celiac plexus block for treatment of cancer pain: a meta-analysis.
Anesth Analg.
1995;
80
290-295
- 277
Wong G Y, Schroeder D R, Carns P E. et al .
Effect of neurolytic celiac plexus block on pain relief, quality of life, and survival
in patients with unresectable pancreatic cancer: a randomized controlled trial.
Jama.
2004;
291
1092-1099
- 278
Stefaniak T, Basinski A, Vingerhoets A. et al .
A comparison of two invasive techniques in the management of intractable pain due
to inoperable pancreatic cancer: neurolytic celiac plexus block and videothoracoscopic
splanchnicectomy.
Eur J Surg Oncol.
2005;
31
768-773
- 279
Arends J, Bodoky G, Bozzetti F. et al .
ESPEN Guidelines on Enteral Nutrition: Non-surgical oncology.
Clin Nutr.
2006;
25
245-259
- 280
Arends J, Zuercher G, Fietkau R. et al .
DGEM Leitlinie Enterale Ernährung: Onkologie.
Akt Ernähr Med.
2003;
28
61-68
- 281
Bjelakovic G, Nikolova D, Gluud L L. et al .
Mortality in randomized trials of antioxidant supplements for primary and secondary
prevention: systematic review and meta-analysis.
Jama.
2007;
297
842-857
- 282
Wigmore S J, Falconer J S, Plester C E. et al .
Ibuprofen reduces energy expenditure and acute-phase protein production compared with
placebo in pancreatic cancer patients.
Br J Cancer.
1995;
72
185-188
- 283
Gordon J N, Trebble T M, Ellis R D. et al .
Thalidomide in the treatment of cancer cachexia: a randomised placebo controlled trial.
Gut.
2005;
54
540-545
- 284
Jatoi A, Windschitl H E, Loprinzi C L. et al .
Dronabinol versus megestrol acetate versus combination therapy for cancer-associated
anorexia: a North Central Cancer Treatment Group study.
J Clin Oncol.
2002;
20
567-573
- 285
Loprinzi C L, Kugler J W, Sloan J A. et al .
Randomized comparison of megestrol acetate versus dexamethasone versus fluoxymesterone
for the treatment of cancer anorexia/cachexia.
J Clin Oncol.
1999;
17
3299-3306
- 286
Moss A C, Morris E, Mac Mathuna P.
Palliative biliary stents for obstructing pancreatic carcinoma.
Cochrane Database Syst Rev CD004200.
2006;
- 287
Hausegger K A, Thurnher S, Bodendorfer G. et al .
Treatment of malignant biliary obstruction with polyurethane-covered Wallstents.
AJR Am J Roentgenol.
1998;
170
403-408
- 288
Isayama H, Komatsu Y, Tsujino T. et al .
A prospective randomised study of „covered” versus „uncovered” diamond stents for
the management of distal malignant biliary obstruction.
Gut.
2004;
53
729-734
- 289
Speer A G, Cotton P B, Russell R C. et al .
Randomised trial of endoscopic versus percutaneous stent insertion in malignant obstructive
jaundice.
Lancet.
1987;
2
57-62
- 290
Urbach D R, Bell C M, Swanstrom L L. et al .
Cohort study of surgical bypass to the gallbladder or bile duct for the palliation
of jaundice due to pancreatic cancer.
Ann Surg.
2003;
237
86-93
- 291
DiFronzo L A, Egrari S, O’Connell T X.
Choledochoduodenostomy for palliation in unresectable pancreatic cancer.
Arch Surg.
1998;
133
820-825
- 292
Aranha G V, Prinz R A, Greenlee H B.
Biliary enteric bypass for benign and malignant disease.
Am Surg.
1987;
53
403-406
- 293
Song H Y, Shin J H, Yoon C J. et al .
A dual expandable nitinol stent: experience in 102 patients with malignant gastroduodenal
strictures.
J Vasc Interv Radiol.
2004;
15
1443-1449
- 294
Kaw M, Singh S, Gagneja H. et al .
Role of self-expandable metal stents in the palliation of malignant duodenal obstruction.
Surg Endosc.
2003;
17
646-650
- 295
Smith T J, Khatcheressian J, Lyman G H. et al .
2006 update of recommendations for the use of white blood cell growth factors: an
evidence-based clinical practice guideline.
J Clin Oncol.
2006;
24
3187-3205
- 296
Rizzo J D, Lichtin A E, Woolf S H. et al .
Use of epoetin in patients with cancer: evidence-based clinical practice guidelines
of the American Society of Clinical Oncology and the American Society of Hematology.
J Clin Oncol.
2002;
20
4083-4107
- 297
Bokemeyer C, Aapro M S, Courdi A. et al .
EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer:
2006 update.
Eur J Cancer.
2007;
43
258-270
- 298
Schuchter L M, Hensley M L, Meropol N J. et al .
2002 update of recommendations for the use of chemotherapy and radiotherapy protectants:
clinical practice guidelines of the American Society of Clinical Oncology.
J Clin Oncol.
2002;
20
2895-2903
Prof. Guido Adler
Klinik für Innere Medizin I,
Universitätsklinikum Ulm
Robert-Koch-Straße 8
89081 Ulm
Telefon: ++ 49/7 31/50 04 45 00
Fax: ++ 49/7 31/50 04 45 02
eMail: guido.adler@uniklinik-ulm.de
